Global specialty pharmaceutical company Innocoll (INNL) has received a Refusal to File letter from the US Food and Drug Administration (FDA) for its Xaracoll drug, which is the company’s product candidate for the treatment of patients suffering from post-surgical pain.

After carrying out a preliminary review, the agency came to the conclusion that the application was not sufficiently complete to allow a substantive review.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The application was submitted by the company in October last year.

In the Refusal to File letter, the FDA, among several other things, indicated Xaracoll is a drug / device combination that calls for Innocoll to submit additional information.

"In the Refusal to File letter, the FDA, among several other things, indicated Xaracoll is a drug / device combination that calls for Innocoll to submit additional information."

Innocoll chief executive officer Tony Zook said: “We expect to work with the FDA over the coming weeks in an effort to address the open issues and to define a path forward for a successful re-filing of our application at the earliest point in time.”

See Also:

Innocoll will request a Type A meeting with the FDA to respond to a wide range of issues that requires to be addressed, as well as seek clarification of what additional information, if any, should be submitted by the company.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

After discussions with the agency, additional details will be disclosed by the company.

Xaracoll drug is a surgically implantable and bio-resorbable bupivacaine-collagen matrix, which uses the company’s CollaRx proprietary collagen-based delivery technology.

The drug is being developed to offer sustained post-surgical pain relief to the patients directly into the surgical site, as well as reduce the need for systemic opioids and their related risks.